Registry, Aug 31, 2027
Dosing n/r
VEGFR2 TKI (with paclitaxel) · Asan Medical Center
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
GIST pipeline
Programs by company or class, across phase, filing, approval, and a stop.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
14 of 17 programs on this matrix
| Phase 2 | Phase 3 | Filed | Approved | Discontinued | |
|---|---|---|---|---|---|
| Asan Medical Center1 program | Registry, Aug 31, 2027 Dosing n/r VEGFR2 TKI (with paclitaxel) · Asan Medical Center | ||||
| Ascentage Pharma1 program | Registry, Mar 31, 2027 every other day, oral tablet multi-kinase TKI · Ascentage Pharma | ||||
| Bayer1 program | Approved once daily, days 1 to 21 of 28, oral tablet multi-kinase TKI · Bayer | ||||
| Blueprint Medicines1 program | Approved once daily, oral tablet KIT/PDGFRA type I TKI · Blueprint Medicines | ||||
| Centre Leon Berard1 program | Registry, Oct 2027 Dosing n/r anti-PD-L1 (with imatinib) · Centre Leon Berard | ||||
| Cogent Biosciences1 program | FDA PDUFA target action date (GIST, with sunitinib), Nov 30, 2026 both once daily, continuous, oral KIT type I TKI plus type II TKI combination · Cogent Biosciences | ||||
| Deciphera Pharmaceuticals2 programs | Registry, May 2028 Dosing n/r Class not reported · Deciphera Pharmaceuticals | Registry, Dec 2027 once daily, oral tablet switch-control KIT/PDGFRA TKI · Deciphera Pharmaceuticals | |||
| GSK1 program | Registry, Mar 10, 2027 once daily, oral tablet selective KIT TKI · GSK | ||||
| Merck1 program | Registry, Nov 18, 2032 Dosing n/r HIF-2 alpha inhibitor · Merck | ||||
| Ningbo Newbay Technology Development1 program | Registry, Aug 2028 twice daily, oral selective KIT TKI · Ningbo Newbay Technology Development | ||||
| Novartis1 program | Approved once daily, oral tablet KIT/PDGFRA TKI (type II) · Novartis | ||||
| Peking University1 program | Registry, Jul 30, 2027 Dosing n/r anti-PD-L1 (with regorafenib) · Peking University | ||||
| Pfizer1 program | Approved once daily, Schedule 4/2, oral capsule multi-kinase TKI (type II) · Pfizer |